The first study by Zhang and Schluesener [42] evaluated a 10-day oral administration of histone deacetylase inhibitor MS-275, an anti-inflammatory and immunomodulatory pharmacological agent, in APP/PS1 mice, a transgenic mouse model of AD exhibiting a remarkable elevation of β-amyloid production associated with typical cognitive and behavioral changes. The gene discussed is APP; the disease is Alzheimer disease.